P.209 Prevalence of healthcare conditions and services used by patients with myotonic dystrophy (DM) pre- and post-diagnosis: A real-world data analysis

Abstract

DM types 1 and 2 are dominantly inherited multisystem disorders that cause progressive weakness and myotonia along with variable cardiopulmonary, gastrointestinal, endocrine, and neurological manifestations that adversely affect quality of life. Literature describing the DM patient journey is limited. To describe the changes in outcomes (healthcare conditions, services, costs, and care days) we analyzed PharMetrics deidentified-US-claims (Jan-2010—Mar-2021) for patients with DM compared with matched controls (MCs) two years post-pre diagnosis. DM-patients had ≥2 DM claims ≥30 days apart (index date=first diagnosis date). Cohorts were matched (5-MC:1-DM) on index date, age, region, gender, plan, and payer types. Outcomes were compared two-years post-diagnosis minus two-years pre-diagnosis (Post-PreDx) using US agency for healthcare research & quality (AHRQ) categories. Data reported is per-member-per-year. All reported findings were significant (p<0.05). We identified 519 DM-patients and 2595 MCs. Most outcomes demonstrated higher care utilization in DM-patients than MCs. Post-PreDx care days increased at all service settings except lab for both cohorts (↑9.9 DM vs ↑1.5 MCs). Post-preDx DM-patients' AHRQ-prevalence changed in 58 (↑57↓1) categories led by "other nervous system disorders" (37.6% DM vs 3.2% MCs), "cardiac dysrhythmias" (17.3% DM vs 2.3% MCs) and "other lower respiratory disease" (16.0% DM vs 2.7% MCs). DM-patients' mean number of services increased post-preDx (21.3 vs 2.9 MCs). Post-preDx DM-patients' utilization increased in 21 AHRQ-service and 7 AHRQ-cost categories. Total medical and drug costs increased for DM-patients' (↑$6,889 to $25,594) vs MCs (↑$1,044 to $6,684). Health care utilization increased significantly in DM patients following diagnosis and was overall both higher and in different categories than MCs. This likely reflects the need to evaluate and manage previously unsuspected manifestations of DM following formal diagnosis.